Neurocritical Care

, Volume 13, Issue 1, pp 57–61 | Cite as

Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients

  • Andrew M. Naidech
  • James Paparello
  • Storm M. Leibling
  • Sarice L. Bassin
  • Kimberly Levasseur
  • Mark J. Alberts
  • Richard A. Bernstein
  • Kenji Muro
Original Article

Abstract

Background

Hyponatremia is common in neurocritical care and is associated with poor outcome, but the optimal treatment is not known. We wished to test the hypothesis that for neurocritical care patients with severe hyponatremia (Na < 130 mmol/l) or hyponatremia (Na < 135 mmol/l) with depressed Glasgow Coma Scale (GCS) that conivaptan use would lead to increased serum sodium compared to usual care.

Methods

We prospectively screened 249 neurocritical care patients with hyponatremia for a prospective, randomized pilot (goal N = 20) trial. Study interventions were usual care, or usual care plus conivaptan 20 mg IV as a bolus followed by 20 mg IV over 24 h, the lower FDA-approved dose. Patients were prospectively followed for changes in serum and urine electrolytes and clinical examinations with a blinded examiner. This study is registered at www.clinicaltrials.gov (NCT00727090).

Results

Despite the prevalence of hyponatremia, recruitment was difficult, and the study was terminated after six patients were enrolled, three in each group. Most hyponatremia in screened but non-randomized patients was transient or not associated with depressed GCS. Conivaptan led to higher serum sodium compared to usual care. The change in serum sodium from baseline, the pre-specified endpoint, was significantly different between groups at six (7.0 ± 1.7 vs. −0.6 ± 2.1 mmol/l, P = 0.008), 24 (9.7 ± 3.2 vs. 0 ± 1.0 mmol/l), and 36 h (8.0 ± 5.6 vs. −1.7 ± 2.1 mmol/l, P = 0.05). There were no apparent differences in clinical examination as a result of treatment. Adverse events were similar, and all randomized patients completed the protocol.

Conclusions

Despite an inclusive protocol, most patients were not candidates for conivaptan therapy for hyponatremia. The role of conivaptan in the Neuro-ICU remains to be defined.

Keywords

Conivaptan Hyponatremia Syndrome of inappropriate antidiuretic hormone secretion Critical care 

Notes

Acknowledgments

This study was funded by Astellas Pharma, US. The study sponsor had no role in the design of the protocol, recruitment of patients, analysis or decision to submit for publication. AMN is responsible for data integrity and the statistical analysis. AMN acknowledges past research support from NovoNordisk, the Neurocritical Care Society, and the Northwestern Memorial Foundation for an unrelated project. AMN acknowledges research support from Gaymar Inc unrelated to this study.

References

  1. 1.
    Nathan BR. Cerebral correlates of hyponatremia. Neurocrit Care. 2007;6:72–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Bhardwaj A. Neurological impact of vasopressin dysregulation and hyponatremia. Ann Neurol. 2006;59:229–36.PubMedCrossRefGoogle Scholar
  3. 3.
    Tisdall M, Crocker M, Watkiss J, Smith M. Disturbances of sodium in critically ill adult neurologic patients: a clinical review. J Neurosurg Anesthesiol. 2006;18:57–63.PubMedCrossRefGoogle Scholar
  4. 4.
    Katayama Y, Haraoka J, Hirabayashi H, Kawamata T, Kawamoto K, Kitahara T, Kojima J, Kuroiwa T, Mori T, Moro N, Nagata I, Ogawa A, Ohno K, Seiki Y, Shiokawa Y, Teramoto A, Tominaga T, Yoshimine T. A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38:2373–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin v2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.PubMedCrossRefGoogle Scholar
  6. 6.
    Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA. Acute hemodynamic effects of conivaptan, a dual v1a and v2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–23.PubMedCrossRefGoogle Scholar
  7. 7.
    Wright WL, Asbury WH, Gilmore JL, Samuels OB. Conivaptan for hyponatremia in the neurocritical care unit. Neurocrit Care. 2009;11:6–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care. 2009;11:14–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med. 1997;126:57–62.PubMedGoogle Scholar
  10. 10.
    Koenig MA, Bryan M, Lewin JL III, Mirski MA, Geocadin RG, Stevens RD. Reversal of transtentorial herniation with hypertonic saline. Neurology. 2008;70:1023–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Andrew M. Naidech
    • 1
  • James Paparello
    • 2
  • Storm M. Leibling
    • 1
  • Sarice L. Bassin
    • 1
  • Kimberly Levasseur
    • 3
  • Mark J. Alberts
    • 1
  • Richard A. Bernstein
    • 1
  • Kenji Muro
    • 4
  1. 1.Department of NeurologyNorthwestern UniversityChicagoUSA
  2. 2.Department of Internal MedicineNorthwestern UniversityChicagoUSA
  3. 3.Northwestern Memorial HospitalChicagoUSA
  4. 4.Department of Neurological SurgeryNorthwestern UniversityChicagoUSA

Personalised recommendations